Cite
HARVARD Citation
Kanni, T. et al. (2021). MABp1 targeting interleukin‐1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open‐label extension period. Clinical and experimental dermatology. pp. 162-163. [Online].